AWA
RXRX icon

Arete Wealth Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Arete Wealth Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,500
Closed -$104K – 655
2025
Q4 		$104K Sell
25,500
-14,044
-36% -$69.6K 0.01% 743
2025
Q3 		$193K Sell
39,544
-50,900
-56% -$267K 0.01% 731
2025
Q2 		$458K Buy
90,444
+77,650
+607% +$381K 0.03% 433
2025
Q1 		$68K Buy
12,794
+1,138
+10% +$8.3K 0.01% 699
2024
Q4 		$78K Hold
11,656
– – 0.01% 725
2024
Q3 		$77K Buy
+11,656
New +$83.6K 0.01% 683

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arete Wealth Advisors's RXRX Position: Q1 2026 in Review

Arete Wealth Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 25,500 shares — an estimated $104K sold.

Arete Wealth Advisors first reported a position in RXRX in Q3 2024 and held it in 6 quarters. The position peaked at $458K in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Arete Wealth Advisors reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arete Wealth Advisors sold 25,500 Recursion Pharmaceuticals shares in Q1 2026, an estimated $104K.
  • Arete Wealth Advisors first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 6 quarters.
  • Arete Wealth Advisors's Recursion Pharmaceuticals position peaked at $458K in Q2 2025.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Arete Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.